APA

Baird R. D., van Rossum A. G. J., Oliveira M., Beelen K., Gao M., Schrier M., Mandjes I. A. M., Garcia-Corbacho J., Vallier A., Dougall G., van Werkhoven E., Linossi C., Kumar S., van Tinteren H., Callari M., Beddowes E., Perez-Garcia J., Rosing H., Platte E., Nederlof P., Schot M., de Vries Schultink A., Bernards R., Saura C., Gallagher W., Cortès J., Caldas C. & Linn S. C. (20200910). POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients. : Clinical cancer research : an official journal of the American Association for Cancer Research.

Chicago

Baird Richard D, van Rossum Annelot G J, Oliveira Mafalda, Beelen Karin, Gao Meiling, Schrier Mariette, Mandjes Ingrid A M, Garcia-Corbacho Javier, Vallier Anne-Laure, Dougall Greig, van Werkhoven Erik, Linossi Constanza, Kumar Sanjeev, van Tinteren Harm, Callari Maurizio, Beddowes Emma, Perez-Garcia José-Manuel, Rosing Hilde, Platte Else, Nederlof Petra, Schot Margaret, de Vries Schultink Aurelia, Bernards René, Saura Cristina, Gallagher William, Cortès Javier, Caldas Carlos and Linn Sabine C. 20200910. POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients. : Clinical cancer research : an official journal of the American Association for Cancer Research.

Harvard

Baird R. D., van Rossum A. G. J., Oliveira M., Beelen K., Gao M., Schrier M., Mandjes I. A. M., Garcia-Corbacho J., Vallier A., Dougall G., van Werkhoven E., Linossi C., Kumar S., van Tinteren H., Callari M., Beddowes E., Perez-Garcia J., Rosing H., Platte E., Nederlof P., Schot M., de Vries Schultink A., Bernards R., Saura C., Gallagher W., Cortès J., Caldas C. and Linn S. C. (20200910). POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients. : Clinical cancer research : an official journal of the American Association for Cancer Research.

MLA

Baird Richard D, van Rossum Annelot G J, Oliveira Mafalda, Beelen Karin, Gao Meiling, Schrier Mariette, Mandjes Ingrid A M, Garcia-Corbacho Javier, Vallier Anne-Laure, Dougall Greig, van Werkhoven Erik, Linossi Constanza, Kumar Sanjeev, van Tinteren Harm, Callari Maurizio, Beddowes Emma, Perez-Garcia José-Manuel, Rosing Hilde, Platte Else, Nederlof Petra, Schot Margaret, de Vries Schultink Aurelia, Bernards René, Saura Cristina, Gallagher William, Cortès Javier, Caldas Carlos and Linn Sabine C. POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients. : Clinical cancer research : an official journal of the American Association for Cancer Research. 20200910.